Download
s00432-021-03572-z.pdf 562,80KB
WeightNameValue
1000 Titel
  • Elotuzumab spares dendritic cell integrity and functionality
1000 Autor/in
  1. Schlaweck, Sebastian |
  2. Strauss, Leon |
  3. Daecke, Solveig |
  4. Brossart, Peter |
  5. Heine, Univ.-Prof. Dr. med. Annkristin |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-02
1000 Erschienen in
1000 Quellenangabe
  • 147(7):2167-2170
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-021-03572-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164573/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized.!##!Methods!#!This study included a total of 45 irAE in patients with metastatic melanoma who were treated with ICI. All patients underwent a complete work-up with exclusion of other causes. Longitudinal blood samples were analyzed for a panel of soluble markers and compared to baseline and to patients who did not experience any irAE. Measurements included LDH, interleukin (IL)-6, IL-1β, IL-17, C-reactive protein (CRP) and tumor necrosis factor (TNF)-alpha as well as tumor markers S100 and melanoma inhibitory activity (MIA).!##!Results!#!During the early onset of irAE increases in serum IL-6 (from mean 24.4 pg/ml at baseline to 51.0 pg/ml; p = 0.003) and CRP (from mean 7.0 mg/l at baseline to 17.7 mg/l; p = 0.001) and a decrease in MIA (from mean 5.4 pg/ml at baseline to 4.8 pg/ml; p = 0.035) were detected. No changes in IL-17 were noted. These effects were observed for irAE of different organ systems.!##!Conclusion!#!Increases of a combination of IL-6 and CRP serum levels can be used for the early detection of irAE and tailored management. Interestingly, changes in MIA serum levels also correlate with irAE onset.
1000 Sacherschließung
lokal Multiple myeloma
lokal Elotuzumab
lokal Immunophenotyping [MeSH]
lokal T cell activation
lokal Humans [MeSH]
lokal Antineoplastic Agents, Immunological/pharmacology [MeSH]
lokal Antibodies, Monoclonal, Humanized/pharmacology [MeSH]
lokal Dendritic cells
lokal Biomarkers [MeSH]
lokal Letter to the Editor
lokal Dendritic Cells/physiology [MeSH]
lokal Dendritic Cells/drug effects [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-3239-5444|https://frl.publisso.de/adhoc/uri/U3RyYXVzcywgTGVvbg==|https://frl.publisso.de/adhoc/uri/RGFlY2tlLCBTb2x2ZWln|https://frl.publisso.de/adhoc/uri/QnJvc3NhcnQsIFBldGVy|https://orcid.org/0000-0002-5298-9880
1000 Hinweis
  • DeepGreen-ID: 7a33d2ec9e3c406387cfc4dd46b2710e ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Elotuzumab spares dendritic cell integrity and functionality
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6449912.rdf
1000 Erstellt am 2023-05-09T10:34:35.162+0200
1000 Erstellt von 322
1000 beschreibt frl:6449912
1000 Zuletzt bearbeitet Sat Oct 14 00:33:14 CEST 2023
1000 Objekt bearb. Sat Oct 14 00:33:14 CEST 2023
1000 Vgl. frl:6449912
1000 Oai Id
  1. oai:frl.publisso.de:frl:6449912 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source